Life Sciences & Healthcare

Netherlands

We work for top 100 enterprise. For example farmaceutical companies ranked in the global top 20. Furthermore, nine out of ten of the global producers of medical instruments are part of our client base. To our lawyers – who often have an in-house history in your industry themselves – your industry has no secrets. The marketing of medicinal products. Public procurement. Pricing and reimbursement. The protection of patents. Or agreements for clinical trials. We know what you are talking about. That is why we assist our top clients with their strategic decisions, the structuring of their business transactions and in legal proceedings.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology and medical devices. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

In M&A the firm has a good reputation for working in the hospitality, life sciences and oil and gas sectors.

IFLR1000, 2018

"They always provide good advice that's commercially sound and legally accurate."

Chambers Global, 2018

"Great knowledge and geographical coverage across Europe."

Chambers Global, 2018

"The client service and responsiveness are exceptional."

Chambers Europe, 2018

Choose area

    Pharmaceuticals

    Pharmaceutical and healthcare law focuses on all the special legislation and legal aspects to do with medicine provision, biotechnology and healthcare. Whether it concerns manufacturing, operations, licences, rates, quality, market regulation or care insurance, there is specific legislation for all these areas.

    Read more
    30/01/2017
    China Lifes­ci­ences Up­date and Pre­dic­tions for 2017
    Sub­scribe to Life Sci­ences & Health­care top­ics

    Feed

    Show only
    Dr. Roland Wiring
    Sep 2018
    Di­git­isa­tion in health­care: From uto­pia to real­ity...
    #law­volu­tion
    22 Nov 18
    CMS Glob­al Life Sci­ences & Health­care For­um
    The Big Bang - Tech­no­lo­gies re­volu­tion­ising Life Sci­ences...
    24/08/2018
    Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
    On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
    June 2018
    De­liv­er­ing qual­ity ad­vice you can act on
    An­nu­al Re­view 2017 – 2018
    25/01/2018
    European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
    In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.
    21/06/2017
    The Ver­dict - Round-up of cor­por­ate crime de­vel­op­ments across CMS
    We are pleased to send our new is­sue of The Ver­dict, an at-a-glance round-up of re­cent leg­al de­vel­op­ments in re­la­tion to cor­por­ate crime. In this is­sue, the spot­light is on some sig­ni­fic­ant changes to anti-cor­rup­tion laws in the Czech Re­pub­lic, in­clud­ing.
    06/03/2017
    PIP-case: ECJ cla­ri­fies scope of no­ti­fied body’s re­spons­ib­il­it­ies...
    In the PIP-case, a French man­u­fac­turer sup­plied thou­sands of wo­men with (al­legedly) de­fect­ive breast im­plants. Amongst oth­ers, pa­tients in Ger­many star­ted lit­ig­a­tion against the no­ti­fied body in ques­tion - TÜV Rhein­land (“Tuv”).
    10/02/2017
    In­dia Budget 2017 - 2018
    On 1 Feb­ru­ary, Fin­ance Min­is­ter Ar­un Jait­ley presen­ted In­dia’s an­nu­al Uni­on Budget for 2017-2018 (the “Budget”) for the fisc­al year be­gin­ning 1 April 2017. The cent­ral aim in this year’s Budget ap­pears to fo­cus on the most vul­ner­able with in­creased spend­ing.
    05/12/2016
    ABS Reg­u­la­tion - Draft Bi­otech Sec­tor Stake­hold­er Guid­ance
    Views are be­ing sought from in­ter­ested stake­hold­ers on European guid­ance for the bi­o­tech­no­logy sec­tor con­cern­ing the EU’s ac­cess to ge­net­ic re­sources and shar­ing of be­ne­fits from util­isa­tion le­gis­la­tion – namely the ABS Reg­u­la­tion.
    05/07/2016
    Leg­al de­vel­op­ments in product li­ab­il­ity: With re­strict­ive le­gis­la­tion...
    The med­ic­al in­dustry is un­der in­creas­ing leg­al pres­sure these days ow­ing mainly to a con­sumer-friendly risk en­vir­on­ment. This is evid­ent from re­strict­ive le­gis­la­tion and re­cent land­mark cases, such as the PIP case, con­cern­ing a French com­pany that sup­plied.